# Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

> **NCT05537766** · PHASE2 · TERMINATED · sponsor: **Kite, A Gilead Company** · enrollment: 19 (actual)

## Conditions studied

- Relapsed/Refractory Waldenstrom Macroglobulinemia
- Relapsed/Refractory Richter Transformation
- Relapsed/Refractory Burkitt Lymphoma
- Relapsed/Refractory Hairy Cell Leukemia

## Interventions

- **BIOLOGICAL:** Brexucabtagene Autoleucel
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05537766
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-01
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-01-27
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate study.
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05537766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05537766, "Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05537766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*